Prognostic Analysis and Risk Prediction Model Establishment of Extremity Osteosarcoma Based on Vasculogenic Mimicry-related Molecule MIG-7
10.3971/j.issn.1000-8578.2021.20.0521
- VernacularTitle:基于血管生成拟态相关分子MIG-7的四肢骨肉瘤预后分析及风险预测模型构建
- Author:
Ke REN
1
;
Nan YAO
;
Sujia WU
;
Xin SHI
;
Chao LI
;
Jun LU
Author Information
1. Department of Orthopaedics, Zhongda Hospital, Southeast University, Nanjing 210009, China
- Publication Type:Research Article
- Keywords:
Osteosarcoma;
Vasculogenic mimicry;
MIG-7;
Nomogram
- From:
Cancer Research on Prevention and Treatment
2021;48(1):31-37
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the relation between vasculogenic mimicry (VM) and MIG-7 in osteosarcoma, as well as their roles in the prognosis, and to establish a model for predicting the prognosis of osteosarcoma. Methods VM was identified by CD31/PAS double-staining in 156 cases of AJCC stage Ⅱ extremity osteosarcoma. Tumor samples were also immunohistochemically stained for MIG-7 to determine whether it was associated with the occurrence of VM. Univariate and multivariate Cox regression analyses were used to identify prognostic factors and a prognostic nomogram for predicting 3- and 5-year OS and MFS was constructed. C-index and calibration curves were used to verify the predictive accuracy of the model. Results The MIG-7 expression in osteosarcoma tissues was associated with VM formation, but MIG-7 expression was not associated with gender, age, AJCCⅡA/ⅡB stage, tumor location, surgical type or histological response to pre-operative chemotherapy. Survival analysis showed that MIG-7 expression, VM and pre-operative chemotherapy were identified as three independent prognostic factors. The value of C-index in nomogram was greater than 0.7. The predicted calibration curve was similar to the standard curve. Conclusion MIG-7 accelerates the progression of osteosarcoma by promoting VM formation, and may also affect prognosis through other mechanisms. The nomogram could afford accurate prognosis prediction and individualized diagnosis and treatment for osteosarcoma patients.
